Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

These are Insider's biggest healthcare stories for the week ending July 9.

We visited Moderna's labs - Amazon's healthcare push - Who owns medical practices

BioNTech SE

Pfizer

Maybe, but it's still too soon to know for sure.

Could Pfizer and Moderna Be in Trouble After the Latest COVID Vaccine Findings?

Moderna (MRNA) doses the first participant in a phase I/II study on its quadrivalent mRNA-based vaccine candidate, mRNA-1010, against seasonal influenza.

Moderna (MRNA) Begins Dosing in Study on mRNA Flu Vaccine

Novavax

COVID-19 concerns are driving the vaccine stocks higher.

Why Moderna and Novavax Stocks Are Jumping Today

AstraZeneca

Johnson & Johnson

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

Inovio Pharmaceuticals

Ocugen, Inc.

Stock markets moved slightly higher despite general worries.

With COVID-19 Variant Threats Rising, Why Are Vaccine Stocks Falling?

Moderna Inc (NASDAQ: MRNA) has initiated a Phase 1/2 study and dosed the first patient with mRNA1010, its quadrivalent vaccine for seasonal flu. The candidate is designed to target lineup lineages that include influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.

Moderna Puts Its First Seasonal Flu Vaccine In The Clinic

Moderna is aiming to employ the technology used to make its Covid-19 shot to produce a more effective flu vaccine.

Moderna Begins Human Study Of MRNA-Based Flu Shot After Covid Success

Shares of Moderna Inc. were down 0.6% in premarket trading on Wednesday after the company said it began dosing patients in a Phase 1/2 clinical trial evaluating an experimental seasonal flu vaccine. The study is expected to enroll 180 adults and test a vaccine candidate against Type A and Type B influenzas.

Moderna begins Phase 1/2 trial for experimental flu vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna Announces First Participant Dosed in Phase 1/2 Study of its Quadrivalent Seasonal Flu mRNA Vaccine

Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine

It's possible, but the dynamics of the fight against COVID-19 are changing rapidly.

Could Pfizer and Moderna Now Face Their Second-Worst Scenario?

Equifax

NVIDIA

CNBC's Jim Cramer on Tuesday looked at some of the best-performing stocks of the second quarter as the latter half of 2021 gets under way.

Cramer reviews Nvidia, Moderna, Equifax and other top-performing stocks of the second quarter

South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the country.  The country is ready to offer the capacity to make up to 1 billion doses immediately, Reuters reports, citing a senior government official.

South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters

Moderna's market value has risen dramatically. The biotech company is now valued at $94B. Moderna trades at a very high P-S ratio of 5.9 as the market expects Moderna to become a $50B company by 2030.

Moderna: Why I Am Selling Half

Boeing

Advanced Micro Devices

Microsoft

NIKE

Stocks rose again Friday, with the S&P 500 and Nasdaq Composite both reaching record highs, and the Dow Jones Industrial Average climbing 1% for the week. Make the most of this market with this week's trending stocks.

The Boeing Company Among this Week's Trending Stocks

New data from Israel appears to be weighing on both vaccine stocks.

Why BioNTech and Moderna Stocks Are Slipping Today

Amgen

Biogen

Intellia Therapeutics

Regeneron Pharmaceuticals

Repligen

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

3 Biotech Stocks Poised to Gain in the Second Half of 2021

Moderna stock is up by almost 7% over the last week (five trading days) and currently trades at about $235 per share. The stock also remains up by a solid 23% over the last month.

Will Moderna Stock Rally Further As It Tests New Highs?

1 Great Reason to Buy Moderna (and It Has Nothing to Do With the COVID Vaccine)

eXp World Holdings Inc

Ideaya Biosciences Inc

iQIYI

Seres Therapeutics

Mitek Systems

Plug Power

Poshmark

Riot Blockchain

TG Therapeutics

Twist Bioscience Corp

Vuzix

These July selections are the current top positive and negative forensic stocks based on combined scores from four different forensic algorithms. The past 5 Negative Forensic portfolios have returned: Jan 2021 +16.7%, July 2020: +114.1%, Feb 2020: +64.9%, Dec 2019: +59.0%, Oct 2019: +108.2%.

Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021

Growing concern over the emerging delta variant and more long-term supply agreements boosted the stock last month.

Why Moderna Shares Surged 27% in June

AMC's business rebound hinges in large part on how well these companies' businesses perform.

3 Stocks to Buy That Are Critically Important to AMC's Future

It ensures the biotech a solid clinical development and regulatory path.

This 1 Decision May Help Moderna Stay Ahead of the Game

And it could mean more bad news for AstraZeneca.

Why Coming in Second Could Be Great News for Pfizer and Moderna

And it could equal billions of dollars for these vaccine leaders.

News for Moderna Stock (MRNA)